Sectoral Asset Management Inc. Has $810,000 Stock Holdings in BeOne Medicines Ltd. – Sponsored ADR $ONC

Sectoral Asset Management Inc. trimmed its position in BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) by 63.0% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 2,665 shares of the company’s stock after selling 4,536 shares during the period. Sectoral Asset Management Inc.’s holdings in BeOne Medicines were worth $810,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the company. Legal & General Group Plc lifted its stake in shares of BeOne Medicines by 0.3% in the 4th quarter. Legal & General Group Plc now owns 54,185 shares of the company’s stock valued at $16,462,000 after acquiring an additional 163 shares during the last quarter. Jefferies Financial Group Inc. bought a new position in shares of BeOne Medicines in the 4th quarter valued at $1,884,000. Global Retirement Partners LLC lifted its stake in shares of BeOne Medicines by 1,051.7% in the 4th quarter. Global Retirement Partners LLC now owns 334 shares of the company’s stock valued at $101,000 after acquiring an additional 305 shares during the last quarter. Leonteq Securities AG bought a new position in shares of BeOne Medicines in the 4th quarter valued at $35,000. Finally, ABN Amro Investment Solutions lifted its stake in shares of BeOne Medicines by 111.1% in the 4th quarter. ABN Amro Investment Solutions now owns 32,076 shares of the company’s stock valued at $9,745,000 after acquiring an additional 16,879 shares during the last quarter. 48.55% of the stock is currently owned by institutional investors.

Insider Transactions at BeOne Medicines

In other news, SVP Chan Henry Lee sold 341 shares of BeOne Medicines stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $300.00, for a total value of $102,300.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders sold 1,005 shares of company stock worth $308,907. 6.19% of the stock is owned by company insiders.

BeOne Medicines Price Performance

Shares of NASDAQ:ONC opened at $310.25 on Monday. The firm has a market cap of $34.04 billion, a P/E ratio of 69.41 and a beta of 0.50. The company has a quick ratio of 3.27, a current ratio of 3.64 and a debt-to-equity ratio of 0.20. BeOne Medicines Ltd. – Sponsored ADR has a 12-month low of $235.35 and a 12-month high of $385.22. The business has a fifty day simple moving average of $300.77 and a 200 day simple moving average of $321.47.

BeOne Medicines (NASDAQ:ONC) last announced its earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. The business had revenue of $1.51 billion during the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. Analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post 5.65 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on ONC shares. Barclays increased their price target on BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Leerink Partners increased their price target on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a research note on Friday, May 15th. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Wolfe Research started coverage on BeOne Medicines in a research note on Friday, March 27th. They issued an “outperform” rating and a $340.00 price target for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research note on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, BeOne Medicines has an average rating of “Moderate Buy” and an average price target of $389.15.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.